ArticleAmerican journal of translational research2025
Immunotherapy combined with targeted therapy and transcatheter arterial chemoembolization: a promising approach for advanced liver cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical efficacy of combining immunotherapy and targeted therapy with transcatheter arterial chemoembolization (TACE) for advanced liver cancer.
methodsA retrospective analysis was performed on 144 patients with advanced liver cancer, divided into three groups based on treatment choice: TACE group, the TACE + immunotherapy group, and the TACE + immunotherapy + targeted therapy group, with 48 patients in each group. Short-term efficacy, T lymphocyte subsets (CD4+, CD8+, CD4+/CD8+), Th1/Th2 cytokines (interleukin-2 [IL-2], tumor necrosis factor-alpha [TNF-α], IL-4, IL-6), tumor markers (carcinoembryonic antigen, alpha-fetoprotein, carbohydrate antigen 199 [CA199], CA125), angiogenesis-related factors (vascular endothelial growth factor, vascular endothelial growth factor receptor, basic fibroblast growth factor, platelet-derived growth factor), and liver function indicators (alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin), adverse reactions, and long-term prognosis were compared.
resultsDisease control rates for the three groups were 47.92%, 56.25%, and 77.08%, respectively. Objective response rates were 19.00%, 25.00%, and 45.83% (all P < 0.05). The combined therapy group showed significantly improved CD4+, CD8+, CD4+/CD8+, tumor markers, angiogenesis factors, and liver function indicators compared to the other groups (all P < 0.05). Progression-free and cumulative survival rates were also significantly better in the combined therapy group (both P < 0.05).
conclusionCombining immunotherapy and targeted therapy with TACE offers significant advantages in treating advanced liver cancer, including improved tumor control, enhanced survival, better liver function, reduced tumor marker levels, and enhanced immune response, with a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.